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ABSTRACT 
 
Seasonal variation of baseline diagnosis (or clinical suspect) of stage I-III colorectal cancer patients 
has been repeatedly reported as an independent variable influencing overall survival. However, data 
are conflicting and no information is available about such a rhythm in advanced stage patients. To 
test whether a circannual rhythm of efficacy outcomes can be detected in this setting, we collected 
data about response rate (RR), progression free survival (PFS), and overall survival (OS) to first-
line chemotherapy of 1610 newly diagnosed metastatic patients treated at four independent centers. 
Responses to first-line chemotherapy were available for 1495 patients. A strong circannual rhythm 
in RR was evident, with the higher proportion of responding patients in the subgroup diagnosed in 
January (acrophase). At the time of data cut-off, 1322 patients progressed and 986 died, with 
median PFS and OS of 11 and 25.6 months, respectively. A circannual rhythmicity of the 
proportion of patients progressing at 6 months and surviving at 1 year was demonstrated, with 
acrophases located both in winter (February and January, respectively), similarly to what reported 
for RR. Several interpretations about the genesis of this cyclic variation could be claimed: the 
rhythm in sunlight exposure and, as a consequence, of vitamin D serum levels and folate 
degradation, the variability in toxic effect intensity of chemotherapy, and the rhythm in the 
biological behavior of tumor cells. This observation is worth of further investigation both in 
preclinical and clinical settings in order to better elucidate the underlying mechanisms. 
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 INTRODUCTION 
 
There is a growing body of evidence that the season of baseline diagnosis may affect survival of 
patients with different solid tumors, including breast and colorectal cancer (CRC). Available data, 
mainly from large epidemiological studies, are conflicting with some studies reporting better 
survival for those patients diagnosed in summertime (Mason BH et al., 1990; Robsahm TE et al., 
2004), while another paper supported the alternative hypothesis (Joensuu H & Toikkanen S, 1991) 
and finally an additional study that did not show any seasonal variation (Galea MH & Blamey RW, 
1991). More specifically, a Norwegian study reported an increased death risk in patients bearing 
stage I-III CRC diagnosed in wintertime (Moan J et al., 2010), whereas a Finnish study in the same 
disease setting demonstrated a worse prognosis for patients diagnosed in summertime (Sankila R et 
al., 1993). 
Possible explanations for this variability in survival claim for the circannual rhythm of sun exposure 
and consequently of serum vitamin D levels, but the existence of conflicting data may argue in 
favour of potential confounding factors. For instance, the efficacy of adjuvant and subsequently of 
palliative chemotherapy at the time of the recurrence of the disease, both affecting overall survival, 
might be dependent from the presence of a plausible circannual rhythmicity in tumour 
aggressiveness and chemosensitivity. 
The issue remains largely unexplored and consequently through a large multi-institutional 
retrospective database we aimed to investigate whether the clinical outcomes of patients with 
advanced CRC treated with first-line chemotherapy showed a rhythmical circannual variation 
according to the month of baseline diagnosis of metastatic disease. 
 
PATIENTS AND METHODS 
 
Patients 
From 1996 up to 2013 data about clinical characteristics and outcomes of consecutive CRC patients 
diagnosed and treated for metastatic disease in four Italian institutions (University of Torino, 
Oncologia Medica, AOU San Luigi di Orbassano; University of Torino, IRCCS Candiolo; 
University of Oriental Piedmont, AOU Maggiore della Carità, Novara; and Colorectal Cancer Unit, 
AOU Città della Salute, Torino) have been included in a clinical database including the following 
variables: patients’ clinical and pathological characteristics, date of diagnosis and sites of first 
distant metastasis, date of first progression, chemotherapy history (if any), efficacy outcomes 
including disease free interval, date of death or last follow-up visit. Date of diagnosis was defined 
as the date of the first appearance of a metastasis in patients with metachronous disease, whereas it 
was the date of surgical intervention in resected patients or the date of colonoscopy in patients with 
synchronous disease. Chemotherapy was started within 4 and 6 weeks from diagnosis in non-
surgical and surgical patients, respectively. Patients received first-line chemotherapy according to 
each institution protocol and for a minimum period of time of at least 6 months, unless otherwise 
contraindicated. The Institutional Review Boards of the participating Centres approved data 
collection. 
 
Outcomes evaluation 
Treatment response was classified according to the UICC criteria (Miller AB et al., 1981) up to 
2001, and then according to RECIST criteria (Eisenhauer EA et al., 2009). Complete response (CR) 
was defined as the complete disappearance of all clinically detectable malignant disease. As far as 
the UICC criteria is concerned, a partial response (PR)  was characterized as a decrease >50% in the 
sum of the products of the two longest perpendicular diameters of all measurable lesions and a 
progressive disease (PD) was defined as an increase of at least 25% in the size of measurable 
lesions and the development of new lesions. According to the RECIST criteria, the definition of PR 
and PD are a decrease >30% and an increase >20% of the sum of the longest diameters of the target 
lesions, respectively. Only the best tumor response was recorded. 
Progression free survival (PFS) and overall survival (OS) were estimated from the start of first-line 
treatment until disease progression or death or date of the last follow-up. The cut-off date for 
statistics computation was December 1st, 2014. Patients not progressing or alive or lost to follow-up 
at the time of data computation were censored at the time of the last follow-up examination. 
 
Statistical analyses 
Survival curves, proportion of patient at risk of progression at 6 months and at risk of death at one 
year were calculated and plotted using the Kaplan-Meier method and validated using the log-rank 
test. Differences between proportions were validated by the Chi-Square test, with Yates’ correction 
when necessary. Non-parametric variables were analyzed  using the Mann-U-Whitney test, whereas 
the parametric variables by the t-test for means. Rhythms were characterized and validated by two-
way ANOVA and by COSINOR analysis (Halberg F, 1969). In the COSINOR analysis, a 
predetermined period (τ=24 h) is fitted to the cosine curves (yi=M+A cos (Φ+θτi)+ei) and their 
significance is evaluated by the least-square method. This analysis yields three main parameters: 
MESOR (M, Midline Estimating Statistics Of the Rhythm of the fitted cosine curve); acrophase (Φ, 
occurrence of maxima in hours, which may not take place at the time during which maximum 
concentration was observed); and double amplitude (2A, the difference between the highest and 
lowest point of the fitted cosine curve). Correlation coefficient constant and mean square error 
determine the goodness-of-fit of the cosine curve. 
These statistical computations were performed using the SPSS for Windows and STATISTICA for 
Windows software. 
 
RESULTS 
 
Patients 
A total of 1610 patients were included in the study and patients’ characteristics are summarized in 
Table 1. Median age was 63.7 years (range 26.8-89.5). Males were predominant (963 patients, 
59.8%), most of the patients presented with synchronous metastases (898 patients, 55.8%), and the 
primary tumors were mainly located in the colon (1137 patients, 70.6%). The majority of metastatic 
lesions were detected in the liver (68.6%), followed by lung (26.3%). Characteristics of the patients 
according to centers were well balanced with no statistically significant differences in the 
proportion of liver or lung involvement, of synchronous or metachronous metastases, gender, 
performance status, grading, stage at diagnosis (Chi-Square p values for all these comparisons 
>0.05), and age (t-test p=0.54). The highest and the least number of diagnosis were recorded in 
April (164) and in September (105), respectively. There was no difference in the number of patients 
stratified according to the month of diagnosis and to centers (two way ANOVA F=0.621, DF=33, 
p=0.95).  
 
Response Rate 
Response rate to first line chemotherapy was available for 1495 patients (92.9%): 580 at center 1 
(96.5%); 535 at center 2 (99.1%); 247 at center 3 (91.5%); and 133 at center 4 (66.8%). Sixty-three 
patients did not receive chemotherapy due to age and/or to concomitant chronic co-morbidities, 
while information about objective response was missed in 52 patients (3.2%). Overall, partial or 
complete response was documented in 577 patients (38.6%). Response rate according to the month 
of diagnosis is summarized in Figure 1. The highest tumor response rate (46.1%) was evident in 
patients diagnosed with metastatic disease on January, whereas the least response rate (27.3%) was 
recorded in the group diagnosed on August. An evident circannual variation of this outcome was 
validated by COSINOR analysis (Fig. 2) with a MESOR of 37.7%, double amplitude of 11.1% and 
acrophase in January (p<0.001). The circannual rhythmicity was evident in all centers (Table 2), 
with superimposable MESORs and acrophases in winter. Similar rhythms were reported for patients 
stratified according to gender (Table 2) (ANOVA p=0.8). A non statistically significant trend for a 
lower response rate and a delayed acrophase was reported in older patients (ANOVA p=0.14). 
Finally, it was not possible to demonstrate a circannual variation in response rates in patients with 
PS>0. 
 
Time to progressive disease 
At the data cut-off of December 1, 2014 a total of 1322 patients already progressed (82.1%). Data 
on tumor progression after first-line chemotherapy were not available for the 63 patients not treated, 
and in 12 patients for whom any information about chemotherapy was lacking. Two hundred and 
thirteen patients did not progressed at the time of data analysis or were lost to follow-up. 
Median overall progression free survival (PFS) was 11.0 months. Median PFS for each center were 
11.2, 10.3, 12.5, and 10.0 respectively (p=ns). 
The proportion of patients not having progressed at 6 months after the beginning of chemotherapy 
stratified according to the month of diagnosis of metastatic disease presented a significant 
circannual variation (Fig. 3) validated by the COSINOR analysis. Characteristics of the curve were 
as follows: MESOR 79%, double amplitude 5.2% and acrophase in the month of February 
(p<0.001). COSINOR analyses for each center are summarized in Table 2. Circannual variations 
were evident for centres 1, 3, and 4, but not for centre 2. A general acrophase concordance was 
reported in winter. No difference in circannual rhythms was evident in patients stratified according 
to gender, age and PS (Table 3). 
 
Overall survival 
At the time of data analysis, 986 (61.2%) patients died, with a median follow-up of 21.4 months. 
Overall median survival of the entire population was 26.5 months and the proportion of surviving 
patients at one year was 80.9%. Median overall survival time (OS) for each center was: 23.0, 26.7, 
31.3, and 27.7 months, respectively (p<0.001). A significant variation according to a circannual 
pattern was evident (Fig. 4), with a MESOR of 80.0%, double amplitude of 4.2% and the acrophase 
in January (p=0.05). COSINOR analysis validated rhythmicity of centers 1 and 3 (Table 2). In these 
two centers, the highest proportion of surviving patients at one year was recorded for those 
diagnosed in January. No difference in circannual rhythms was evident in patients stratified 
according to gender, age and PS (Table 3).  
 
Dose of 5-FU delivered to patients 
The total dose of 5-FU administered to patients during first line chemotherapy was elaborated in 
center 1, were data were available for 588 patients. Median 5-FU dose (range) was 32,500 (2,000-
94,800) mg/sqm. COSINOR analysis confirmed a circannual rhythmicity in the dose administered 
with MESOR=32,217 mg/sqm, double amplitude of 3,250 mg/sqm and the acrophase in January 
(p= 0.05). A circannual rhythm was also demonstrated when considering 5FU dose intensity, with 
MESOR of 1,512 mg/sqm/week, double amplitude of 174 mg/sqm/week, and acrophase in February 
(p<0.001). 
 
DISCUSSION 
This is the first report showing a circannual variation of the activity and efficacy of first-line 
chemotherapy in terms of response rate, progression free survival and overall survival in patients 
with metastatic colorectal carcinoma, with best outcomes recorded in patients diagnosed in winter.  
Chronobiological studies are difficult to carry on in clinical settings especially because large 
numbers are required. We then planned to collect data from four independent institutions managing 
metastatic colorectal cancer patients. Distribution of the patients was homogeneous with no major 
differences demonstrated. Even though a lower number of patients were diagnosed in August (i.e. 
the month traditionally dedicated to vacation in Italy), no difference in the incidence of diagnosis 
between months and centers was evident. The great majority of the patients received an oxaliplatin- 
or irinotecan- containing first line chemotherapy which have been demonstrated to be 
superimposable in determining patient outcome (Tournigand C et al., 2004). 
Our data clearly showed a robust circannual rhythm of antitumor drug activity, with best response 
rates in patients diagnosed in winter. This circannual pattern was demonstrated in all the four 
centers participating in the study representing an internal validation of the results. Differences in 
MESOR and Double Amplitude of Center 4 could be explained by the lower patient sample which 
magnifies statistical errors. Similar rhythmic variations were demonstrated for patients stratified 
according to gender, whereas no rhythms and lower response rates were recorded in older and in 
symptomatic patients (PS>0). This is in line with what already published in these latter patient 
subgroups (Campos Costa I et al. 2013; Pugliese P et al. 2002). The circadian variation in response 
rate was further validated by the presence of a synchronized rhythm for progression free survival 
rate at six months. No differences were shown when patients were stratified according to gender, 
age or PS. The absence of such a rhythm in one center could be explained by chance or by 
institutional differences in determining tumor progression that may have smoothened variability as 
demonstrated by its double amplitude of only 7%. As far as the circannual variation in survival rate 
at one year is concerned, an overall rhythm has been demonstrated with the best survival rate shown 
for those patients diagnosed in winter, further confirming the evidence that patients diagnosed 
between December and February are those having the best outcomes. Survival rhythm, however, is 
fair less definitive as demonstrated by the results stratified according to centers. This may be due to 
differences in second and third line treatments that have been shown to affect overall survival 
(Heinemann V et al., 2014). This possible explanation is further supported by the statistically 
validated differences in median OS that we observed between centers.  
Differences in OS according to the season of diagnosis have been shown for several tumors (Mason 
BH et al., 1990; Robsahm TE et al., 2004; Joensuu H & Toikkanen S, 1991), and particularly for 
colorectal cancer patients. A potential explanation claims for the circannual variations of sun 
exposure and consequently, of the circulating vitamin D serum levels. In fact, since the beginning of 
2000s, it was proposed that vitamin D is a protective factor against colorectal cancer (Garland CF & 
Garland FC, 2006). This hypothesis arose from the analysis of the geographic distribution of colon 
cancer deaths in the US, that were higher in areas where people were exposed to inferior amounts of 
natural light such as in the larger cities and rural areas at high latitudes. The hypothesis was also 
supported by a comparison of colon cancer mortality rates in areas that vary in mean daily solar 
radiation penetrating the atmosphere (Borisenkov MF., 2011). The relationship between vitamin D 
levels and patient outcomes was recently confirmed in a prospective study involving 1598 Scottish 
patients with stage I-III CRC, where high pre-surgery vitamin D levels was associated to a longer 
OS (Zgaga L et al., 2014). However, this hypothetical explanation hardly fit with our observation. 
In fact, nearly 82% of metastatic CRC patients are vitamin D insufficient (Ng K, 2011; Zgaga L et 
al., 2014) and thus the presence of a circannual rhythm is at least questionable. Moreover, patients 
submitted to 5FU chemotherapy are asked to limit sun exposure in order to reduce skin toxicities. 
The highest progression rate shown in those patients diagnosed in August (Fig. 1) could rather 
suggest an inverse relationship between vitamin D level and response to chemotherapy, contrasting 
with what above reported. Indeed, our data cannot be completely compared to what already 
published (Mason BH et al., 1990; Robsahm TE et al., 2004; Joensuu H & Toikkanen S, 1991; 
Galea MH & Blamey RW, 1991; Moan J et al., 2010; Sankila R et al., 1993), as we took into 
account metastatic patients instead of completely resected patients, and then specific investigations 
should be conducted. 
Another potential explanation rely on the onset of toxicities such as diarrhea and vomiting that may 
lead to a dehydration status more often in summer than in winter due to weather condition. In fact, 
median summer temperature in Northern Italy raises 30°C. As a consequence, patients diagnosed in 
summer and with chemotherapy start during the hottest months of the year are those that had more 
dose reductions and thus a low drug dose-intensity. In center 1, where data were available, we 
demonstrated a circannual rhythm in the total dose of 5FU administered to patients, with the 
acrophase in the month of January, and in 5FU dose intensity, with the acrophase in the month of 
February, confirming the hypothesis. This may have influenced our observation as it has been 
repeatedly demonstrated that there is a direct correlation between the total dose of 5-FU 
administered and the treatment outcome (Garufi C et al. 1997; Gamelin EC1, Danquechin-Dorval 
EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra 
FG. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients 
with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer. 1996 Feb 
1;77(3):441-51). 
Another intriguing hypothesis that may explain these discrepancies in outcomes comes from 
Norwegian researchers (Steindal AH et al., 2007). These Authors postulated that the folate 
degradation induced by UV exposure could be one of the potential causes of the observed 
differences in survival among resected cancer patients. This intriguing theory raises another 
important issue worth of discussion. Because folate is a modulator of 5-fluorouracil (5-FU) 
antitumor activity, its putative degradation by UV may reduce drug efficacy.  
Finally, it has been shown a circannual variation in tumor cell proliferation in non-Hodgkin’s 
lymphomas (Smaaland R et al, 1993) and in thyroid tumors (Akslen LA & Sothern RB, 1998), with 
acrophases in winter for both studies. Consequently, we may further hypothesize that chemotherapy 
is more active in wintertime as tumor cells are more proliferating. 
In conclusion, we showed for the first time a circannual variation of outcomes in patients diagnosed 
with metastatic colorectal cancer and treated with first line chemotherapy. Best response rate, 
progression free survival and overall survival rates were recorded in patients diagnosed in winter.  
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FIGURE LEGENDS  
 
Figure 1. Responses to first line chemotherapy according to the month of diagnosis of metastatic 
disease (PD: progressive disease: SD: stable disease: Resp: response). 
 
Figure 2. COSINOR analysis of response rate according to months of diagnosis of metastatic 
disease (MESOR=37.7%; 2A=11.1%; Acrophase=January. P<.001). 
 
Figure 3. COSINOR analysis of the probability of progression at 6 months according to months of 
diagnosis of metastatic disease (MESOR=79%; 2A=5.2%; Acrophase=February. P<.001). 
 
Figure 4. COSINOR analysis of survival probability at 1 year according to month of diagnosis of 
metastatic disease (MESOR=80%; 2A=4.2%; Acrophase=January. p=.05). 
Table 1. Characteristics of the patients included in the study 
 Total Center 1 Center 2 Center 3 Center 4 
Number of patients (%) 1610 601 (37.3) 540 (33.5) 270 (16.8) 199 (12.4) 
      
Male (%) 
Female (%) 
963 (59.8) 
647 (40.2) 
371 (61.7) 
230 (38.3) 
311 (57.6) 
229 (42.4) 
166 (61.5) 
104 (38.5) 
115 (57.8) 
84 (42.2) 
Median age at 
diagnosis years (range) 
63.7 (26.8-89.5) 62.8 (28.9-
82.9) 
62.5 (26.8-
84.9) 
65.5 (29.6-
87.4) 
68.9 (32.9-
89.5) 
Characteristics of primary 
Stage at diagnosis (%) 
I 
II 
III 
IV 
Unknown 
 
13 (0.8) 
194 (12.0) 
433 (26.9) 
898 (55.8) 
72 (4.5) 
 
4 (0.7) 
75 (12.5) 
148 (24.6) 
372 (61.9) 
2 (0.3) 
 
2 (0.4) 
61 (11.3) 
126 (23.3) 
293 (54.3) 
58 (10.7) 
 
1 (0.4) 
40 (14.8) 
89 (33.0) 
129 (47.8) 
11 (4.0) 
 
6 (3.0) 
18 (9.0) 
70 (35.2) 
104 (52.3) 
1 (0.5) 
Site of primary (%) 
Colon 
Rectum 
Unknown 
 
1137 (70.6) 
421 (26.1) 
52 (3.3) 
 
429 (71.4) 
170 (28.3) 
2 (0.3) 
 
380 (70.4) 
112 (20.7) 
48 (8.9) 
 
181 (67.0) 
88 (32.6) 
1 (0.4) 
 
147 (73.9) 
51 (25.6) 
1 (0.5) 
Grading (%) 
1 
2 
3 
Unknown 
 
32 (2.0) 
726 (45.1) 
342 (21.2) 
510 (31.7) 
 
13 (2.2) 
308 (51.2) 
146 (24.3) 
134 (22.3) 
 
7 (1.3) 
138 (25.6) 
101 (18.7) 
294 (54.4) 
 
5 (1.9) 
173 (64.1) 
56 (20.7) 
36 (13.3) 
 
7 (3.5) 
107 (53.8) 
39 (19.6) 
46 (23.1) 
      
Months of diagnosis of metastatic disease - No. of patients (%) 
January 134 (8.3) 44 (7.3) 46 (8.5) 27 (10.0) 17 (8.5) 
February 124 (7.7) 46 (7.6) 33 (6.1) 19 (7.0) 26 (13.1) 
March 150 (9.3) 64 (10.6) 39 (7.2) 20 (7.4) 27 (13.6) 
April 164 (10.2) 64 (10.6) 55 (10.2) 23 (8.5) 22 (11.1) 
May 152 (9.4) 63 (10.5) 36 (6.8) 32 (11.9) 21 (10.6) 
June 132 (8.2) 39 (6.6) 58 (10.7) 23 (8.5) 12 (6.0) 
July 135 (8.4) 44 (7.3) 54 (10.0) 25 (9.3) 12 (6.0) 
August 110 (6.8) 42 (7.0) 41 (7.6) 15 (5.6) 12 (6.0) 
September 105 (6.6) 44 (7.3) 32 (5.9) 20 (7.4) 9 (4.5) 
October 144 (8.9) 54 (9.0) 53 (9.8) 27 (10.0) 10 (5.0) 
November 118 (7.3) 42 (7.0) 46 (8.5) 18 (6.7) 12 (6.0) 
December 142 (8.9) 55 (9.2) 47 (8.7) 21 (7.7) 19 (9.6) 
      
Metastases (%) 
Synchronous 
Metachronous 
Unknown 
 
767 (47.6) 
795 (49.4) 
48 (3.0) 
 
259 (43.1) 
342 (56.9) 
0 (0) 
 
285 (52.8) 
207 (38.3) 
48 (8.9) 
 
124 (45.9) 
146 (54.1) 
0 (0) 
 
99 (49.8) 
100 (50.2) 
0 (0) 
Median Disease Free 
Interval (Range) 
11.4 mo (1-
217.7) 
8.2 (1-
217.7) 
17.2 (1-
103.7) 
10.3 (1-
138.9) 
13.0 (1-
102.5) 
Site of metastasis (%)      
Liver 1105 (68.6) 419 (69.7) 373 (69.1) 183 (67.8) 130 (65.3) 
Lung 423 (26.3) 158 (26.3) 104 (19.3) 103 (38.1) 58 (29.1) 
Local 238 (14.8) 79 (13.1) 68 (12.6) 42 (15.6) 49 (24.6) 
Other (Peritoneum, 377 (23.4) 142 (23.6) 120 (22.2) 66 (24.4) 49 (24.6) 
Ovary, etc) 
Performance Status at 
study entry (%) 
0 
1-2 
3-4 
Unknown 
 
 
639 (39.7) 
449 (27.9) 
16 (1.0) 
506 (31.5) 
 
 
238 (39.6) 
245 (40.8) 
8 (1.3) 
110 (18.3) 
 
 
133 (24.6) 
61 (11.3) 
0 (0) 
346 (64.1) 
 
 
205 (75.9) 
61 (22.6) 
1 (0.4) 
3 (1.1) 
 
 
63 (31.7) 
82 (41.2) 
7 (3.5) 
47 (23.6) 
Chemotherapy (%)      
5FU based 394 (24.5) 181 (30.1) 89 (16.5) 95 (35.2) 29 (14.6) 
5FU + Oxaliplatin 
based 
861 (53.5) 375 (62.4) 327 (60.6) 101 (37.4) 58 (29.1) 
5FU + Irinotecan based 154 (9.6) 9 (1.5) 99 (18.3) 22 (8.1) 24 (12.1) 
5FU + Oxaliplatin + 
Irinotecan based 
9 (0.6) 0 (0) 2 (0.4) 5 (1.9) 2 (1.0) 
Chemotherapy + 
Biologicals 
77 (4.8) 15 (2.5) 18 (3.3) 24 (8.9) 20 (10.1) 
Unknown or not 
administered 
115 (7.0) 21 (3.5) 5 (0.9) 23 (8.5) 66 (33.1) 
      
No of patients 
progressed 
1322 (82.1) 521 (86.7) 487 (90.2) 191 (70.7) 123 (61.8) 
No of patients censored 
for progression 
213 (13.2) 80 (23.3) 53 (9.8) 79 (29.3) 1 (0.5) 
No of patients without 
progression data 
75 (4.7)    75 (37.7) 
Overall Progression 
Free Survival (months; 
median - quartiles) 
11.0 (6.8-16.7) 11.2 (6.3-
17.8) 
10.3 (7.0–
16.0) 
12.5 (8.1-
18.9) 
10 (6.7-
13.4) 
      
No of patient died 986 (61.2) 454 (75.5) 382 (71.3) 119 (44.1) 31 (15.6) 
No of patient censored 
for survival 
624 (38.8) 147 (24.5) 158 (28.7) 151 (55.9) 168 (84.4) 
Overall Survival 
(months; median - 
quartiles) 
26.5 (14.5-48.1) 23.0 (11.6-
39.7) 
26.7 (15.2-
54.6) 
31.3 (18.1-
51.1) 
27.7+ 
      
 
 
 
Table 2. COSINOR Analyses of circannual rhythmicity of outcomes according to the month of 
diagnosis of metastatic disease stratified according to center 
 
Response rate (%) 
 MESOR Double Amplitude Acrophase p 
Center 1 35.7 14.8 December <.0001 
Center 2 45.0 4.2 March =.03 
Center 3 34.5 17.8 December =.01 
Center 4 27.4 33.1 February <.001 
Overall 37.7 11.1 January <.001 
     
Patients at risk of progression at 6 months (%) 
 MESOR Double Amplitude Acrophase p 
Center 1 73.4 10.8 January <.0001 
Center 2 79.9 7.0 June ns 
Center 3 78.1 19.0 February <.001 
Center 4 69.8 20.0 December <.001 
Overall 79.0 5.2 February <.001 
     
Survival rates at 1 year (%) 
 MESOR Double Amplitude Acrophase p 
Center 1 72.4 8.4 January <.01 
Center 2 81.7 3.8 April ns 
Center 3 79.4 9.6 January =.06 
Center 4 79.8 6.8 September ns 
Overall 80.0 4.2 January =.05 
 
Table 3. COSINOR Analyses of circannual rhythmicity of outcomes according to the month of 
diagnosis for patients stratified according to main characteristics at diagnosis of metastatic disease. 
 
Response rate (%) 
 MESOR Double Amplitude Acrophase COSINOR 
p 
ANOVA 
p 
Male 38.3 12.7 December <.0001 .80 Female 38.5 12.8 February <.01 
      
Age >70 28.9 16.0 March .15 .14 Age <70 40.4 10.0 December <.0001 
      
PS 0 42.4 10.2 February <.001 <.001 PS 1-2 27.1 9.8 December 0.20 
      
Patients at risk of progression at 6 months (%) 
 MESOR Double Amplitude Acrophase   
Male 79.1 3.6 February .05 .76 Female 76.5 9.8 February <.001 
      
Age >70 71.5 8.0 February .05 .74 Age <70 79.3 8.6 February <.001 
      
PS 0 84.7 8.8 February <.001 .50 PS 1-2 70.1 12.4 February .05 
      
Survival rates at 1 year (%) 
 MESOR Double Amplitude Acrophase   
Male 78.2 2.6 November 0.1 .06 Female 80.4 8.9 February <.001 
      
Age >70 74.6 9.0 March .04 .66 Age <70 80.4 6.4 January .05 
      
PS 0 85.1 7.2 December .1 .19 PS 1-2 68.4 8.6 March .1 
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